about
p73 as a pharmaceutical target for cancer therapyA phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancieNovel therapeutics for aggressive non-Hodgkin's lymphoma.Characterization of an environmental DNA-derived gene cluster that encodes the bisindolylmaleimide methylarcyriarubinProtein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cellsWealth of opportunity - the C1 domain as a target for drug development.Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.Biologically targeted therapeutics in pediatric brain tumors.A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitisAKT pathway in neuroblastoma and its therapeutic implication.In vivo/ex vivo and in situ assays used in cancer research: a brief review.Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.New targets of therapy in T-cell lymphomas.Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cellsApoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase Cβ inhibitor.
P2860
Q28611414-08873A42-1C0A-4C1B-B403-00B9A80B4014Q33418912-35BB0CD6-5A90-45BA-9BCD-47FE45C898B7Q34600909-EDED03BB-3895-4656-AF51-285FC1668265Q34698607-9A2E597D-2418-46C2-A27C-095B3CF70F55Q35000494-520F2256-E224-4890-8937-94CB0E39772FQ35111768-01D7286C-6BDA-47DA-BE3E-D681A4952577Q35125453-0F899B65-D9DF-442F-AF4A-617844E364FDQ35634280-A28269D2-D980-4E8D-B766-CA9E0724EB99Q36168226-E4184623-D230-4803-9EEF-D630C7703A54Q36545784-82C814A7-F0A5-412E-A969-C013CC61C45BQ36844744-E7A13EE3-4471-4C0A-87EE-B7F2D761BFD4Q37109823-140E7C3C-2673-4D69-B5F7-924AB8BCAA7DQ37157311-5F9737C1-68B9-4250-AFD4-D705478C96E2Q37159523-A5E058B2-133E-43B8-B469-93E95CC6180DQ37355404-F21555CA-752A-4E5E-9BA0-A6D197AFDFF9Q37688465-5EE5314F-5A4B-49DF-896F-51CFEE0846FDQ37701472-2BE47634-3733-4033-B5BC-4A35049CEAF1Q37884624-88570853-CDBA-4ABB-BA40-1EED1CCB9CE3Q38311896-6C1536FE-1AB7-4999-B9A7-CFBE1A948A67Q39268126-67E9DF40-03B8-4E17-ABFE-BF5F13B92B4AQ39584277-7DBC8F3C-F7A1-4A38-80A1-73B01601E5E9Q39601989-4EE30138-6748-4376-83CE-BC27EB1A3BDE
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Enzastaurin.
@en
type
label
Enzastaurin.
@en
prefLabel
Enzastaurin.
@en
P1476
Enzastaurin.
@en
P2093
Steven T Rosen
P304
P356
10.1097/CCO.0B013E3282F10A00
P577
2007-11-01T00:00:00Z